Q2/2024 6/30/2024 EPS -0.970 ZacksConsensus -1.090 ActVsEst 0.120 - Beat
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswire
- Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.MarketBeat
JSPR
Earnings
- 5/14/24 - Beat
JSPR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- JSPR's page on the SEC website